Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A+AVD vs ABVD as Frontline Therapy in Advanced Classical Hodgkin Lymphoma
jRCT2080222441Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2014
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by Takeda. Started Mar 2014; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on jRCT2080222441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222441.